Non-exclusive drug discount agreement for Tocilizumab

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Dec 31, 2026 · 125 days left·Open·Supplies·Framework

Inscrivez-vous pour sauvegarder Open documents

Structured notice only

Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tocilizumab (ATC-Code nach WHO: L04AC07)

50/100

Score d'opportunité

Needs reviewLow complexity

SuppliesFrameworkOpen

Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No guaranteed purchase volumes; actual demand may be low or unpredictable, depending on doctor prescriptions and patien...

The buyer may terminate the procedure or the agreement early if exclusive discount agreements are concluded (typically...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Aperçu

Moderate opportunity

Faits clés

Framework procurement
Supplies contract
1 lot
Duration until Dec 2026
Conclusion of non-exclusive discount agreements for Tocilizumab (ATC L04AC07)
Supply of pharmaceutical products to AOK PLUS for patients in Saxony and Thuringia

Afficher le résumé complet

This is a non-exclusive drug discount agreement (Rabattvereinbarung) for Tocilizumab (ATC L04AC07) under an open-house model. Interested pharmaceutical companies can submit participation requests from 03.12.2025 until 31.12.2026. The agreement ends on 31.12.2026. No minimum purchase quantities are guaranteed. The procedure is not a classic public procurement but a voluntary publication for transparency.

Risques

No guaranteed purchase volumes; actual demand may be low or unpredictable, depending on doctor prescriptions and patien...

The buyer may terminate the procedure or the agreement early if exclusive discount agreements are concluded (typically...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

Must be a pharmaceutical company (pharmazeutischer Unternehmer) as per §4 Abs. 18 AMG
Must have registered office in Germany, EU, or EEA (§9 Abs. 2 Satz 1 AMG)

Eligibility

Must submit completed 'Eigenerklärung zum Nichtvorliegen von Ausschlussgründen' (declaration of no exclusion grounds)

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No explicit award criteria; discount rate is the likely award factor.

Acheteur

Nom

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen

Localisation

Erfurt, DEU

[email protected]

Site web

www.aok.de/pk/plus/

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive drug discount agreement for Tocilizumab

Open-house model for concluding non-exclusive discount agreements for Tocilizumab. Covers pharmaceutical supply to AOK PLUS for Saxony and Thuringia.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Dec 2025 - Dec 2026

Catégorie

Pharmaceutical products

Critères d'attribution

No explicit award criteria; discount rate is the likely award factor.

Date limite

Deadline Dec 31, 2026

Détails de la procédure

Date de publication: 20 Oct 2025
Langues: German

Métadonnées de référence

Base juridique: 32014L0024

Identifiants de référence

ID de l'appel d'offres: 690691-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3